REMARKS/ARGUMENTS

By the present amendment, applicants have canceled Claims 12 and 23, therefore, the claims remaining for consideration by the Examiner are Claims 1-11, 13-19, 20-22, and 24.

The foregoing amendments to the specification are to place the Abstract on a separate sheet. The amendments to the claims are to place the claims in better form and remove multiple dependencies. No new matter has been added. Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Attorney for Applicants

Reg. No. 34,940

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7945

Date: January 31, 2005